Water insoluble anticancers have two issues with their use first, toxic surfactants often have to be used to solubilise the drug; and secondly, such drugs not only reach the tumor tissues but also reach and penetrate healthy tissues in the body.
Our novel self dispersing Nanoparticle technology platform addresses these challenges with higher drug localization to the cancer cells, lesser excipient, and a higher dose
Products made with our technology do not need any pre-administration preparation, such as the administration of antihistamines or steroids, or the use of in-line filters.
Two products are under development,
Paclitaxel Injection for nanodispersion (PICN), and
Docetaxel Injection for nanodispersion (DICN)